HMTXF
Hemostemix Inc.·Healthcare
0.05
0.000%(+0.00)
Market ClosedLast Updated: — ET
52W L: $0.0552W H: $0.12
HMTXF NEWS
newsfilecorp.com
Mar 9
Hemostemix Leadership Attending Abundance360 Summit
Calgary, Alberta--(Newsfile Corp. - March 9, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) today announced that Thomas Smeenk CEO and Peter Lacey, Chairman are attending the 2026 Abundance360 Summit in Los Angeles this week. Founded by futurist and entrepreneur Peter H.
newsfilecorp.com
Feb 3
Hemostemix Appoints Renowned Vascular Surgeon and Principal Investigator, Dr. York Hsiang, as Business Consultant to Advance First Nations-Led Healthcare Partnerships
Calgary, Alberta--(Newsfile Corp. - February 3, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous stem cell company treating those who suffer in pain from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, dilated cardiomyopathy, and vascular dementia, in Florida, Canada, The Bahamas, is pleased to announce the appointment of Dr. York Hsiang as a Business Consultant. "Since 2006, the first question I have asked every principal investigator I meet is simple: 'Doctor, does ACP-01 work?
newsfilecorp.com
Jan 16
Hemostemix Receives FDA Support for Its Basket Protocol Approach
Calgary, Alberta--(Newsfile Corp. - January 16, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous stem cell company treating those who suffer in pain from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, dilated cardiomyopathy, and vascular dementia, in Florida, Canada, The Bahamas, announces the successful completion of its pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA). Hemostemix' team included Thomas Smeenk, CEO; Dr. Ina Sarel, Chief Scientific Officer; Dr. Fraser Henderson, Chief Medical Officer, Professor of Neurosurgery and a practicing neurosurgeon; Dr. Ernst von Schwarz, a triple board-certified transplant surgeon, cardiologist and renowned stem cell researcher; and Dr. William Shankle, a neurologist specializing in the prevention, diagnosis, and management of vascular dementia and Alzheimer's.
